A double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly that are responders to octreotide LAR or lanreotide depot (ACROBAT Evolve)
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2019
At a glance
- Drugs CRN-00808 (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms ACROBAT EVOLVE
- Sponsors Crinetics Pharmaceuticals
- 08 Jan 2019 New source identified and integrated (ClinicalTrials.gov Identifier:NCT03792555)
- 01 Jan 2019 Planned primary completion date changed to 1 Jun 2020.
- 01 Jan 2019 Status changed from not yet recruiting to recruiting.